A Prospective Single-Arm Clinical Study of Recasimab in the Treatment of Lorlatinib-Induced Hypercholesterolemia/Mixed Hyperlipidemia (ChiCTR) - Sep 16, 2026 - P4 | N=29 | Not yet recruiting | Sponsor: Hunan Cancer Hospital; Hunan Cancer Hospital
New P4 trial • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia
|